<110>   Hart, Stephen Lewis
         Writer, Michele

<120>   PEPTIDE LIGANDS

<130>   ABL-012.1P US

<140>   (To Be Assigned)
<141>   2005-12-06

<150>   PCT/EP2004/002421
<151>   2004-06-07

<150>   GB 03 13132.3
<151>   2003-06-06

<160>   50

<170>   PatentIn version 3.1

<210>   1
<211>   5
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Peptide ligand
<220>
<221>   MISC_FEATURE
<222>   (2)..(4)
<223>   Xaa at position 2 = any amino acid residue, Xaa at position 3 = a
         ny amino acid residue, Xaa at position 4 = any amino acid residue

<400>   1

Pro Xaa Xaa Xaa Thr
1   5

<210>   2
<211>   4

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand
<220>

<221>   MISC_FEATURE

<222>   (3)..(3)

<223>   Xaa at position 3 = any amino acid residue

<400>   2

Pro Ser Xaa Ser
1

<210>   3

<211>   5

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand

<220>

<221>   MISC_FEATURE

<222>   (2)..(4)

<223>   Xaa at position 2 = any amino acid, Xaa at position 3 = any amino
         acid having an amide side chain, Xaa at position 4 = any amino a
         cid

<400>   3

Gln Xaa Xaa Xaa Gln
1   5

<210>   4

<211>   3

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand

<220>

<221>   MISC_FEATURE

<222>   (2)..(2)

<223>   Xaa at position 2 = any amino acid residue having an aliphatic si
        de chain

<400>   4

Ser Xaa Ser
1

<210>   5

<211>   5

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand

<220>

<221>   MISC_FEATURE

<222>   (2)..(2)

<223>   Xaa at position 2 = any amino acid residue

<220>

<221>   MISC_FEATURE

<222>   (4)..(4)

<223>   Xaa at position 4 = any amino acid residue

<400>   5

Pro Xaa Leu Xaa Thr
1   5

<210>   6

<211>   5

<212>   PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 6

Pro Ala Leu Lys Thr
1   5

<210> 7

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 7

Pro Xaa Asn Xaa Thr
1   5

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 8

Pro Ser Asn Ser Thr
1   5

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 9

Pro Pro Asn Thr Thr
1   5

<210> 10

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid resdue, Xaa at position 3 = an
      y amino acid residue, Xaa at position 4 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = any amino acid resdue

<400> 10

Pro Xaa Xaa Xaa Thr Xaa
1   5

<210> 11

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = any amino acid residue

<400> 11

Pro Xaa Leu Xaa Thr Xaa
1   5

<210> 12

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221>   MISC_FEATURE

<222>   (2)..(2)

<223>   Xaa at position 2 = any amino acid residue

<220>

<221>   MISC_FEATURE

<222>   (4)..(4)

<223>   Xaa at position 4 = any amino acid residue

<220>

<221>   MISC_FEATURE

<222>   (6)..(6)

<223>   Xaa at position 6 = any amino acid residue

<400>   12

Pro Xaa Asn Xaa Thr Xaa
1   5

<210>   13

<211>   6

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand

<220>

<221>   MISC_FEATURE

<222>   (1)..(1)

<223>   Xaa at position 1 = any amino acid residue

<220>

<221>   MISC_FEATURE

<222>   (3)..(5)

<223>   Xaa at position 3 = any amino acid residue, Xaa at position 4 = a
         ny amino acid residue, Xaa at position 5 = any amino acid residue

<400> 13

Xaa Pro Xaa Xaa Xaa Thr
1   5

<210> 14

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (3)..(5)

<223> Xaa at position 3 = any amino acid residue, Xaa at position 4 = a
ny amino acid residue, Xaa at position 5 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa at position 7 = any amino acid residue

<400> 14

Xaa Pro Xaa Xaa Xaa Thr Xaa
1   5

<210> 15

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 15

Ala Pro Ser Asn Ser Thr Ala
1   5

<210> 16

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 16

Ser Pro Ala Leu Lys Thr Val
1   5

<210> 17

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 17

Ser Thr Pro Pro Asn Thr Thr
1   5

<210> 18

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 18

Pro Ser Asn Ser
1

<210> 19

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 19

Pro Ser Leu Ser
1

<210> 20

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = Ala or Lys

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 20

Xaa Pro Ser Xaa Ser
1   5

<210> 21

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 21

Ala Pro Ser Asn Ser
1   5

<210> 22

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 22

Leu Pro Ser Leu Ser
1   5

<210> 23

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 23

Met Leu Pro Ser Leu Ser
1   5

<210> 24

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 24

Pro Met Leu Pro Ser Leu Ser
1   5

<210> 25

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 25

Ser Gln Lys Asn Pro Gln Met
1   5

<210> 26

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 26

Phe Gln Ser Gln Tyr Gln Lys
1   5

<210> 27

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 27

Met Ala Ser Ile Ser Met Lys
1   5

<210>   28

<211>   7

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand

<400>   28

Asp Trp Trp His Thr Ser Ala
1   5

<210>   29

<211>   7

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand

<400>   29

Ser His Val Lys Leu Asn Ser
1   5

<210>   30

<211>   7

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand

<400>   30

Gln Leu Leu Thr Gly Ala Ser
1   5

<210>   31

<211>   7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 31

Thr Ala Arg Asp Tyr Arg Leu
1   5

<210> 32

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 32

Phe Pro Arg Ala Pro His His
1   5

<210> 33

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 33

Ser Glu Trp Leu Ser Ala Leu
1   5

<210> 34

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 34

Ile Gly Gly Ile Arg Arg His
1   5

<210> 35

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 35

Tyr Thr Met Glu Phe Asn Arg
1   5

<210> 36

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 36

Pro Ala Ala Tyr Lys Ala His
1   5

<210> 37

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = any amino acid residue, Xaa at position 4 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = Ala or Val

<400> 37

Pro Xaa Xaa Xaa Thr Xaa
1   5

<210> 38

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue,

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue,

<400> 38

Pro Xaa Asn Xaa Thr
1   5

<210> 39

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A
sn or Leu, Xaa at position 4 = any amino acid residue

<400> 39

Pro Xaa Xaa Xaa Thr
1   5

<210> 40

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position = Thr or Ser

<400> 40

Pro Xaa Asn Xaa Thr
1   5

<210> 41

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = Ala or Leu

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 41

Xaa Pro Ser Xaa Ser
1   5

<210> 42

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A
      sn or Gln, Xaa at position 3 = any amino acid residue

<400> 42

Gln Xaa Xaa Xaa Gln
1   5

<210> 43

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = Leu or Ile

<400> 43

Ser Xaa Ser
1

<210> 44

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide ligand

<400> 44

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Ser His Val Lys Leu Asn Ser Cys Gly
            20   25

<210> 45

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223>   Peptide ligand

<400>   45

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Ala Pro Ser Asn Ser Thr Ala Cys Gly
            20   25

<210>   46

<211>   28

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand

<400>   46

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Met Ala Ser Ile Ser Met Lys Cys Gly
            20   25

<210>   47

<211>   28

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand

<400>   47

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Phe Pro Arg Ala Pro His His Cys Gly
            20   25

<210>   48

<211>   28

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand

<400>   48

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Asp Trp Trp His Thr Ser Ala Cys Gly
                20   25

<210>   49

<211>   28

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand

<400>   49

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly
                20   25

<210>   50

<211>   28

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Peptide ligand

<400>   50

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1   5   10   15

Gly Ala Cys Ala Thr Arg Trp Ala Arg Glu Cys Gly
                20   25